Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov

BACKGROUND: Patient‐reported adverse events (AEs) may be a useful adjunct to clinician‐assessed AEs for assessing tolerability in early phase, dose‐finding oncology trials (DFOTs). We reviewed DFOTs on ClinicalTrials.gov to describe trends in patient‐reported outcome (PRO) use. METHODS: DFOTs commen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai‐Kwon, Julia, Yin, Zhulin, Minchom, Anna, Yap, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607259/
https://www.ncbi.nlm.nih.gov/pubmed/34676991
http://dx.doi.org/10.1002/cam4.4307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607259/
https://www.ncbi.nlm.nih.gov/pubmed/34676991
http://dx.doi.org/10.1002/cam4.4307

Ejemplares similares